Loading…
← CockpitCompetitor Analysis › SOLARA.NS Solara Active Pharma Sciences Ltd.Open in the cockpit ↗

Solara Active Pharma Sciences Ltd.SOLARA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum strong 78
Mkt cap
$334M
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$1.76M
20-day average traded
Fwd P/E
20.7×
forward earnings
ROIC−WACC
-11.6 pp
WACC 16.5%
Hurdle
+42 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · INR₹650.50
1D-2.4%
1W-2.7%
1M+0.8%
3M+18.5%
6M+11.7%
YTD+15.1%
1Y+17.5%
ATR %5.4%
Beta0.69
52w lowhigh16.0% off high

What Solara Active Pharma Sciences does

Employees: 3,108

Solara Active Pharma Sciences at a glance

Size Solara Active Pharma Sciences (SOLARA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $334M, the 1021st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹650.50 on 18 Nov 2026.

Performance Over six months the shares gained 11.7%, against -18.6% for the median peer and +3.8% for the India market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 27.3% over the last twelve months (peer median +2.7%); the operating margin is 8.4% (peer median 2.3%).

Valuation It trades at 20.7× forward earnings against a peer median of 24.9× (3rd cheapest of 6).

Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 11.6 points below its cost of capital (16.5% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026SOLARA.NS 113Peer median 81
Six months, rebased to 100: Solara Active Pharma Sciences against the median of its 20 peers (local-currency closes).

Solara Active Pharma Sciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹15.4B₹13.6B₹12.7B₹12.7B₹14.3B
Revenue growth—+7%0%-11%—
Gross profit₹4.12B₹1.94B₹1.86B-₹1.30B₹1.25B
EBITDA₹2.34B₹1.80B₹1.93B-₹2.83B₹1.19B
Net income₹369M-₹74.1M₹5.40M-₹5.67B-₹222M
Free cash flown/a₹88.8M₹605M-₹316M-₹352M
Capital expendituren/a₹528M₹399M₹411M₹1.11B
Total debt₹5.91B₹6.87B₹7.96B₹10.1B₹10.1B

Quarterly statements and history in the cockpit →

Solara Active Pharma Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%0%+25%+50%1875MYX3015091720002168SECARE005250AVIR368AINO4886INDSWFTLABUNICHEMLABALEMBICLTDSOLARA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Solara Active Pharma Sciences is the large dot.

Fundamentals: revenue growth against valuation

-40%-20%0%+20%0×100×200×300×1875SECARE368A48864569SOLARA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Solara Active Pharma Sciences is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%MYX3015091720002168SECARE600594368A0001530007904569ALEMBICLTDSOLARA.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Solara Active Pharma Sciences is the large dot.

Solara Active Pharma Sciences competitors and peer comparison

How Solara Active Pharma Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Solara Active Pharma Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureSOLARA.NSPeer medianRank in peer set
1-month return+0.8%-6.4%5th highest of 21
6-month return+11.7%-18.6%6th highest of 21
Distance from 52-week high-16.0%-34.9%4th highest of 21
Revenue growth (TTM)+27.3%+2.7%3rd highest of 20
Operating margin8.4%2.3%5th highest of 19
Forward P/E20.7×24.9×3rd cheapest of 6
Growth the price implies (Req g, 7 yrs)38.3%8.0%2nd most demanding of 12
Growth delivered (Del g)-3.2%+4.2%4th lowest of 12
Hurdle (Req g minus delivered)+41.5 pp+2.8 ppmost demanding of 12
ROIC minus cost of capital-11.6 pp-7.1 pp7th lowest of 18
EV / EBITDA15.6×12.6×5th cheapest of 9
Net debt / EBITDA2.2×-0.6×3rd most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Solara Active Pharma Sciences SOLARA.NSIndia$334M+12%+27%8%20.7×38.3%-3.2%
BioDlink International 1875.HKHong Kong$334M-24%-51%-31%288.2×n/an/a
Mayne Pharma MYX.AXAustralia$333M+155%-6%-14%n/a19.0%-0.9%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%n/a9.2%+6.5%
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%n/a-11.5%+10.3%
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%n/a14.3%-14.0%
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%n/an/an/a
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%n/an/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%24.9×6.1%+62.1%
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%n/an/an/a
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
Guizhou Yibai Pharmaceutical 600594.SSChina$351M-23%-26%-15%n/a8.0%-11.3%
Kitazato 368A.TJapan$317M+7%+9%52%12.2×-16.8%+5.4%
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%n/an/an/a
ASKA Pharmaceutical 4886.TJapan$354M-24%+11%n/a12.9×n/an/a
Anhui Fengyuan Pharmaceutical 000153.SZChina$355M-17%-24%3%n/a3.6%+3.1%
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%n/an/an/a
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%n/a27.5%-6.4%
KYORIN Pharmaceutical 4569.TJapan$360M-22%-6%2%35.5×6.7%+4.2%
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%n/an/an/a
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%n/a44.3%+26.7%

Questions

Which companies are Solara Active Pharma Sciences's closest peers?
The cockpit's peer set: BioDlink International (1875.HK), Mayne Pharma (MYX.AX), Kingchem (Liaoning) Life Science (301509.SZ), Standard Chemical & Pharmaceutical (1720.TW), Chongqing Hifuture Information Technology (002168.SZ), Beihai Gofar Chuanshan Biological (600538.SS), Foresee Pharmaceuticals (6576.TWO), Swedencare (SECARE.ST).
Is Solara Active Pharma Sciences expensive compared with its peers?
On forward p/e it trades at 20.7× against a peer median of 24.9×, 3rd cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +42 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Solara Active Pharma Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned +11.7% against -18.6% for the median peer; over one year +17.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.